Clinical Trial Update: Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated daclizumab (Human Anti-Tac) for Juvenile Idiopathic Arthritis-associated uveitis; the study completed and results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Uveitis
• Iritis
• Juvenile Idiopathic Arthritis

Drugs mentioned

• Daclizumab (daclizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Anterior Uveitis, Arthritis, Juvenile Idiopathic | Phase 2 | Status: COMPLETED | Results posted: 2010-09-29